1. Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders provided by a domain expert (right panel).
Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders provided by a domain expert (right panel). Red dots indicate the actual measurements of patients at baseline (before second-line treatment), after 6 and 12 months. Black dots (with error bars) represent the counterfactual predictions and 95% CIs, supposing all patients were treated with that drug class. BMI, body mass index; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide-1 receptor agonists; SU, sulfonylurea; TZD, thiazolidinedione.
Assaf Gottlieb et al. BMJ Open Diab Res Care 2017;5:e000435
©2017 by American Diabetes Association